Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in...
December 12 2016 - 8:30AM
Business Wire
- Publication Describes Work Pertaining
to the Cooperative Research and Development Agreement (CRADA)
between the National Institutes of Health (NIH) and Kite
Pharma
- Kite Pharma Has an Exclusive License
from NIH to Multiple T Cell Receptor (TCR) Product Candidates
Targeting Mutant KRAS to Treat Solid Tumors
- Research and Accompanying Editorial by
Carl H. June, M.D., Published in the December 8, 2016 New England
Journal of Medicine (NEJM)
Kite Pharma, Inc. (Nasdaq:KITE) announced today that
characterizations of T cell receptor candidates which it has
licensed under the Cooperative Research and Development Agreement
(CRADA) with the National Institutes of Health (NIH) have been
published in the December 8, 2016 New England Journal of Medicine
(NEJM).
The research, led by Steven A. Rosenberg, M.D., Ph.D., chief of
the Surgery Branch at NCI’s Center for Cancer Research, and a
scientific collaborator with Kite, describes a patient with KRAS
mutant metastatic colorectal cancer who was successfully treated
with T cells that are reactive to KRAS G12D mutation. This work
follows previously reported treatment of a patient with advanced
cholangiocarcinoma with T cells targeting a mutated erbb2
interacting protein.
“We are very excited to see the results of this landmark study
conducted by Dr. Rosenberg and his team at the NCI. These findings
represent proof of concept that T-cell technology directed against
neoantigens can be utilized to treat solid tumors,” said David
Chang, M.D., Ph.D., Executive Vice President, Research and
Development, and Chief Medical Officer of Kite.
As published in the NEJM publication, mutations in the KRAS gene
are thought to drive 95 percent of all pancreatic cancers and 45
percent of all colorectal cancers. The G12D mutation is the most
common KRAS mutation and is estimated to occur in more than 50,000
new cases of cancer in the United States each year.
In September 2016, Kite announced that it had entered into an
exclusive, worldwide license with NIH for intellectual property
related to multiple TCR-based product candidates for the treatment
of tumors expressing mutated KRAS antigens. These TCR product
candidates were developed in the laboratories of Steven A.
Rosenberg, M.D., Ph.D., and James C. Yang, M.D., of the NCI.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company
engaged in the development of novel cancer immunotherapy products,
with a primary focus on engineered autologous cell therapy (eACT™)
designed to restore the immune system's ability to recognize and
eradicate tumors. Kite is based in Santa Monica, CA. For
more information on Kite Pharma, please visit
www.kitepharma.com. Sign up to follow @KitePharma on Twitter at
www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as "predicts," "believes," "potential,"
"proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should" or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the ability to advance and the success of
TCR-based product candidates directed against KRAS antigens.
Various factors may cause differences between Kite's expectations
and actual results as discussed in greater detail in Kite's filings
with the Securities and Exchange Commission, including without
limitation in its Form 10-Q for the quarter ended September 30,
2016. Any forward-looking statements that are made in this press
release speak only as of the date of this press release. Kite
assumes no obligation to update the forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161212005345/en/
Kite PharmaChristine CassianoSVP, Corporate Communications &
Investor Relationsccassiano@kitepharma.comorGreg MannVP, Investor
Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Jun 2024 to Jul 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Jul 2023 to Jul 2024